Synovial sarcoma is a high-grade soft tissue malignancy, for which current cytotoxic chemotherapies provide limited benefit. Although histone deacetylase (HDAC) inhibitors are known to suppress synovial sarcoma in vitro and in vivo, the exact mechanism is not clear. In this study, we report a central role of the transcription factor, early growth response-1 (EGR1), in the regulation of HDAC inhibitorinduced apoptotic cell death in synovial sarcoma. The SS18-SSX oncoprotein, characteristic of synovial sarcoma, maintains EGR1 expression at low levels, whereas it is significantly increased after HDAC inhibitor treatment. On the contrary, EGR1 knockdown leads to a decrease in HDAC inhibitor-induced apoptosis. Moreover, we find that under these conditions phosphatase and tensin homolog deleted in chromosome 10 (PTEN) is upregulated and this occurs through direct binding of EGR1 to an element upstream of the PTEN promoter. Using a combination of gain-and loss-of-function approaches, we show that EGR1 modulation of PTEN contributes to HDAC inhibitorinduced apoptosis in synovial sarcoma. Finally, restoration of EGR1 or PTEN expression is sufficient to induce synovial sarcoma cell death. Taken together, our findings indicate that SS18-SSX-mediated attenuation of an EGR1-PTEN network regulates synovial sarcoma cell survival, and that HDAC inhibitor-mediated apoptosis operates at least in part through reactivation of this pathway.
Introduction
Early growth response-1 (EGR1) is a zinc finger transcription factor rapidly induced by a wide range of mitogenic stimuli (Sukhatme et al., 1987) with important roles in the regulation of cell growth, differentiation and death (Sukhatme, 1990; Gashler and Sukhatme, 1995) . It has been suggested that EGR1 is a tumor suppressor, as its overexpression can dramatically inhibit tumor cell growth in vitro and in xenografted mice (Huang et al., 1994; Liu et al., 1996) . EGR1 seems to function as a key regulator of cell death and growth through regulation of a number of downstream targets including, transforming growth factor b1, phosphatase and tensin homolog deleted in chromosome 10 (PTEN), p53, p73, FAS, cyclin D2 and cyclin-dependent kinase inhibitor 2D (Liu et al., 1999; Virolle et al., 2001 Virolle et al., , 2003 Krones-Herzig et al., 2005; Yu et al., 2007) . Indeed, loss of EGR1 expression is observed in many human tumors, including breast carcinomas, non-small-cell lung cancers, hematopoietic malignancies, gliomas and sarcomas (Le Beau et al., 1993; Levin et al., 1995; Calogero et al., 1996 Calogero et al., , 2004 Huang et al., 1997; Lubieniecka et al., 2008) . RNA interference (RNAi)-mediated EGR1 suppression was shown to enhance the tumorigenic phenotype of v-sis-transformed NIH/3T3 cells (Huang et al., 1995) , suggesting that reduced endogenous EGR1 expression may correlate with tumor formation. However, the mechanisms underlying EGR1 downregulation in tumorgenesis have not been fully elucidated.
We recently showed that the oncogenic protein SS18-SSX, characteristic of synovial sarcoma, directly participates in EGR1 repression (Lubieniecka et al., 2008) . Synovial sarcoma is a high-grade soft tissue malignancy with a peak incidence in young adults, which exhibits a pathognomonic t(X;18)(p11.2;q11.2) chromosomal translocation (Okcu et al., 2003) . The resulting fusion protein SS18-SSX contains a transcriptional activation domain from SS18 and a repressor domain from SSX (Brett et al., 1997; Lim et al., 1998) . Lacking DNA-binding domains, SS18-SSX dysregulates a number of genes by interacting with SWI/SNF and polycomb-group chromatin remodeling factors (Soulez et al., 1999; Thaete et al., 1999; Nagai et al., 2001) . In previous investigations, enforced SS18-SSX expression was shown to repress EGR1 transcription and promote growth of human fibroblast cells (Nagai et al., 2001; de Bruijn et al., 2006) . In synovial sarcoma, EGR1 expression is maintained at low levels, whereas it is markedly upregulated by SS18-SSX RNAi (Lubieniecka et al., 2008) . We have found that the SS18-SSX protein is directly associated with the EGR1 promoter, and that two polycomb-group repressor factors, BMI-1 and EZH2, interact with the same EGR1 promoter region in an SS18-SSX-dependent manner. It is noteworthy that polycomb-group-mediated histone H3 lysine 27 trimethylation, a key mark of genomic silencing, is tightly correlated with EGR1 repression. These data suggest that EGR1 downregulation occurs as a result of SS18-SSXmediated chromatin remodeling. Indeed, this mechanism has been further supported by the observation that histone deacetylase (HDAC) inhibitors efficiently remove histone H3 lysine 27 trimethylation marks, recruit acetyl groups to histone H3 tails and thereby reactivate expression of EGR1 in synovial sarcoma. However, the precise contribution of EGR1 to synovial sarcoma or HDAC-inhibitor responsiveness of these cells is unclear.
HDAC inhibitors are a group of small molecules that can promote hyperacetylation of histones to alter gene expression and particularly to activate genes that are usually silenced in tumors (Bolden et al., 2006) . In fact, several HDAC inhibitors, such as FK228 (also known as romidepsin and depsipeptide), MS-275, SAHA and PXD101, are being tested in clinical trials (Moradei et al., 2008; Stimson et al., 2009) , and SAHA has recently been approved for use in T-cell lymphomas (Khan and La Thangue, 2008) . At the molecular and cellular levels, it is widely accepted that HDAC inhibitors suppress tumor growth by inducing cyclindependent kinase inhibitor p21/WAF1/CIP1-mediated cell cycle arrest, as well as mitochondrial/cytochrome C-dependent apoptotic cell death (Medina et al., 1997; Archer et al., 1998) . There is also evidence to suggest that HDAC inhibitors affect PTEN expression (Pan et al., 2007; Gan and Zhang, 2009 ); however, the underlying mechanisms have not been resolved.
PTEN is an extremely important phosphatase that regulates the activity of the PI3K/AKT survival pathway (Downes et al., 2001) . Furthermore, in response to various cellular insults, EGR1 has been shown to regulate PTEN expression (Virolle et al., 2001) . We therefore investigated the possibility that EGR1 initiates HDAC inhibitor-mediated apoptosis by serving as an upstream activator of PTEN. In this study, we show a critical role of EGR1 reactivation in HDAC inhibitorinduced apoptosis of synovial sarcoma. The importance of EGR1 in this process is confirmed by the observations that repression of EGR1 by RNAi inhibits HDAC inhibitor-induced PTEN activation and apoptosis, and that EGR1 protein directly binds to the PTEN promoter region after HDAC inhibitor addition. Knockdown of PTEN is able to counteract the effects of both HDAC inhibitors and heterologous expression of EGR1. Furthermore, an EGR1-PTEN network was found to influence synovial sarcoma cell survival, showing that SS18-SSX-mediated attenuation of this pathway enables these cells to escape cell death.
Results

HDAC inhibitors induce synovial sarcoma apoptosis
Romidepsin is an HDAC inhibitor that effectively suppresses synovial sarcoma in vitro and in vivo (Ito et al., 2005) . To test whether HDAC inhibitors induce synovial sarcoma apoptosis, the biphasic synovial sarcoma cell line SYO-1 was cultured in the presence of the membrane-impermeable dye propidium iodide (PI), and then exposed to romidepsin or vehicle. The Cellomics KineticScan Reader was used to count PI-positive cells in a 48-h time course at 2-h intervals. As shown in Figure 1a , treatment with 1 nM romidepsin, but not DMSO, induced a time-dependent increase in the PI-positive cell number, and higher doses of 5 and 10 nM romidepsin further enhanced cell death. Similar results were also obtained using other structurally different HDAC inhibitors (MS-275, PXD101 and SAHA), and using the monophasic synovial sarcoma cell line FUJI (data not shown).
To assess whether HDAC inhibitor-induced cell death is by apoptosis, we next carried out western blots to examine the activation of apoptotic marker caspase-3, as reflected by an increase in its active cleaved form. At 16 h after exposure to three different HDAC inhibitors, romidepsin, MS-275 and PXD101, both SYO-1 and FUJI cells revealed a marked elevation of activated caspase-3 (Supplementary Figure S1 ), indicating that these cells undergo apoptosis following HDAC inhibitor treatment. Consistent with this result, flow cytometry of SYO-1 cells labeled with annexin V and PI shows that romidepsin results in 80-90% of cells positive for annexin V within 16 h (Figure 1b, top) . Caspase-3 activation is inhibited by the broad-spectrum caspase inhibitor z-VAD-fmk (Figure 1b , bottom; compare lanes 2 and 4), and, consistent with a caspase-dependent process, romidepsin-induced apoptosis is dramatically decreased in the presence of z-VAD-fmk. Taken together, these data suggest that apoptosis is a key mechanism by which HDAC inhibitors suppress synovial sarcoma.
EGR1 is specifically upregulated in HDAC inhibitor-mediated synovial sarcoma apoptosis To further characterize HDAC inhibitor action on tumor cells by synovial sarcoma cell lines, SYO-1 and FUJI and human embryonic kidney (HEK293) cells were stained with annexin V and PI, followed by 16-h exposure to DMSO, romidepsin or MS-275, and then subjected to flow cytometry analysis. As illustrated in Figure 1c , treatment with romidepsin and MS-275 strongly induced apoptosis in SYO-1 and FUJI cells, but not in HEK293 cells, relative to DMSO controls. To explore the molecular basis for this finding, we initially focused on the EGR1 tumor suppressor gene because (a) EGR1 functions as an early response factor in multiple apoptotic pathways, (b) EGR1 expression is markedly decreased in synovial sarcoma cell lines and tumors (Supplementary Figure S2) (Lubieniecka et al., 2008) and (c) EGR1 is one of the targets directly inhibited by the synovial sarcoma-associated SS18-SSX fusion protein (15). Consistently, relative to controls, HEK293 cells engineered to express SS18-SSX revealed a clear decrease in EGR1 transcripts, an effect reversed by romidepsin (Supplementary Figure S3) . In light of these EGR1 and PTEN in Synovial Sarcoma L Su et al findings, we performed reverse transcription quantitative PCR (RT-qPCR) to monitor the alteration of EGR1 mRNA levels, and found that treatment with romidepsin or MS-275 increases EGR1 transcription in SYO-1 and FUJI cells, but not in HEK293 cells (Figure 1d ). Furthermore, a similar approach was applied to stable HEK293 cell lines expressing native SS18, SS18-SSX2 or none, showing that romidepsin only stimulates activation of EGR1 in SS18-SSX2-expressing HEK293 cells, rather than in the other two HEK293-derived cell lines (Supplementary Figure S3) . Thus, EGR1 is specifically induced in synovial sarcoma during HDAC inhibitor-stimulated apoptosis. Importantly, we noticed that the elevated EGR1 level seems to correlate with the degree of HDAC inhibitor-induced apoptosis, raising the possibility that EGR1 activation might mediate the apoptotic activity of HDAC inhibitors.
EGR1 knockdown reduces HDAC inhibitor-mediated apoptosis To evaluate the role of EGR1 in the apoptotic response to HDAC inhibitors, we performed transient transfection 
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L Su et al experiments of SYO-1 and FUJI cells with control random or EGR1-specific siRNA. At 24 h after transfection, cells were treated with romidepsin or DMSO, and then subjected to Cellomics kinetic cell death analysis. With EGR1 knockdown (Figure 2a ), si-EGR1-expressing SYO-1 cells showed a significant reduction in romidepsin-induced apoptosis ( Figure 2b ). Similar effects were also observed using the FUJI synovial sarcoma cell line (Supplementary Figure S4) , supporting a requirement for EGR1 reactivation in HDAC inhibitor induction of cell death.
To further confirm the aforementioned findings, we established two EGR1-knockdown SYO-1 cell lines by stably expressing EGR1-specific small hairpin RNA (shRNA). There was no significant difference in cell morphology or growth rate between control and EGR1-knockdown cells (data not shown). Relative to control cells, EGR1 expression was maintained at low levels in both sh-EGR1-expressing cell lines after romidepsin addition, as determined by western blotting analysis (Supplementary Figure S5) . For further studies, the sh-EGR1-1 cell line was selected because of its more efficient knockdown. The time course of lentiviralmediated EGR1 knockdown was examined by RTqPCR analysis, which revealed a more than 70% decrease in EGR1 transcripts by 12 h after romidepsin addition, compared with control cells (Figure 2c ). Expression of EGR1 shRNA significantly inhibited the apoptotic effects of romidepsin (Figure 2d ). Similar results obtained using MS-275 (Supplementary Figure  S6) further implicate EGR1 as a key regulator of HDAC inhibitor-mediated apoptosis.
EGR1-mediated synovial sarcoma apoptosis involves PTEN To evaluate whether EGR1 is alone sufficient to induce apoptosis in synovial sarcoma, we subcloned the EGR1 cDNA upstream of an EGFP expression vector, separated by the internal ribosome entry site-EGFP cassette. The control (internal ribosome entry site-EGFP) or EGR1-internal ribosome entry site-EGFP construct was then transiently transfected into SYO-1 and FUJI cells, and the fate of EGFP-expressing cells was followed. Overexpression of EGR1 dramatically enhanced caspase-3 activation in both cell lines (Figure 3a) , indicating that EGR1-expressing synovial sarcoma cells undergo apoptotic cell death. In addition, we also identified an increase in PTEN protein levels in the cultures expressing EGR1. Given the fact that PTEN has been identified as a direct target of EGR1 in keratinocytes (Virolle et al., 2001) , we sought to explore EGR1 and PTEN in Synovial Sarcoma L Su et al whether a similar EGR1-PTEN pathway was operating in synovial sarcoma. A short region between -1118 and -858 of the human PTEN promoter has been reported to be sufficient for inducing transcriptional activation of PTEN (Ma et al., 2005) . It is important to note that this sequence contains three canonical EGR1-binding sites (Virolle et al., 2001) , which are highly conserved in human and mouse (Figure 3b ). To determine whether EGR1 expressed in synovial sarcoma cells binds to the PTEN promoter, ChIP assays were carried out using control and EGR1-expressing SYO-1 cells. The sequence spanning EGR1-binding sites (P1) and a control upstream sequence (P2) of the human PTEN promoter were amplified by PCR. As shown in Figure 3c , the sequence P1, but not P2, was strongly enriched in the immunoprecipitates obtained with EGR1 antibody from cells expressing EGR1. Thus, EGR1 directly regulates PTEN in synovial sarcoma cells; however, the biological significance of this relationship was unclear.
To assess the functional importance of EGR1-induced activation of PTEN, we next performed transient transfection experiments of SYO-1 cells with PTENspecific siRNA. As shown in Figure 3d , PTEN knockdown effectively depleted the ability of expressed EGR1 to induce apoptosis. To further characterize the role of PTEN, we also overexpressed PTEN in SYO-1 and FUJI cells. Heterologous expression of PTEN led to caspase-3 activation in both tested synovial sarcoma cell lines (Figure 4a) . No apparent change in EGR1 protein levels was detected in cells transfected with or without the PTEN expression vector, suggesting that PTENinduced apoptosis is downstream of EGR1. In support of this idea, expression of PTEN resulted in B50% apoptosis of synovial sarcoma cells in both EGR1 and control shRNA experiments (Figure 4b) . Together, these results show that both EGR1 and PTEN expressions are sufficient to induce synovial sarcoma cell apoptosis, and that PTEN serves as an important effector of EGR1-mediated apoptotic cell death.
HDAC inhibitors increase PTEN expression through EGR1
We next tested the possibility of HDAC inhibitors promoting EGR1-dependent activation of PTEN. First, RT-qPCR analysis using SYO-1 cells revealed a timedependent increase in PTEN mRNA levels after 9-hr exposure to romidepsin. In contrast, EGR1 knockdown strongly inhibited romidepsin-induced PTEN activation, as did PTEN knockdown (Figure 5a ). This finding was also confirmed by western blotting analysis (data not shown). Furthermore, the effect of romidepsin on EGR1 expression seems to be direct, because it is unaffected by the protein synthesis inhibitor cycloheximide (Supplementary Figure S7A) . Conversely, romidepsin-induced activation of PTEN is sensitive to cycloheximide (Supplementary Figure S7B) , consistent with a requirement for de novo synthesis of EGR1.
To investigate this possibility, we performed ChIP assays using SYO-1 cells. As shown in the left panel of Figure 5b , stimulation of these cells with romidepsin resulted in enhanced binding of EGR1 to EGR1-binding sites of the PTEN promoter in a time-dependent manner, which was correlated with elevated EGR1 and, by 9 h, elevated PTEN protein levels (Figure 5b , right). The same experiment was performed in FUJI cells with similar results (data not shown). 
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PTEN is critical for HDAC inhibitor-induced EGR1-dependent apoptosis
Finally, the biological importance of PTEN in the EGR1-dependent response to HDAC inhibitors was examined. Previous studies have shown that enforced PTEN expression can reduce the levels of active phosphorylated AKT (Downes et al., 2001) , and that the AKT signaling pathway is active in synovial sarcoma (Bozzi et al., 2008) . We therefore performed western blots for phosphorylated AKT at Serine 473 (p473-AKT) to monitor the changes in AKT activity after HDAC inhibitor treatment. To this end, SYO-1 cells were transiently transfected with control random, EGR1 or PTEN siRNA. After exposure to romidepsin for 9 h, control synovial sarcoma cells revealed a marked decrease in cellular p473-AKT levels, suggesting inactivation of the AKT pathway. However, romidepsinmediated suppression of AKT phosphorylation was dramatically abolished by knockdown of either EGR1 or PTEN (Figure 6a ). Because EGR1 transactivates PTEN expression in response to HDAC inhibitors (Figure 5a ), these findings implicate HDAC inhibitormediated expression of EGR1 inducing PTEN, which in turn blocks the AKT survival pathway. Consistent with this, in general, p473-AKT levels were observed to closely mirror that of PTEN expression in both loss-and gain-of-function experiments (Figure 6a , Supplemental Figure S8 ). Similar to EGR1 silencing, knockdown of PTEN prolongs survival of SYO-1 cells treated with HDAC inhibitors (Figure 6b) . Together, these results show an important role for HDAC-mediated activation of an EGR1-PTEN network that culminates in decreased activity of AKT survival signaling and consequently synovial sarcoma apoptosis. 
Discussion
Previous studies have characterized EGR1 as a tumor suppressor that functions as a transcription modulator of downstream target genes, in particular those involved in cell cycle arrest and apoptosis (Liu et al., 1999; Virolle et al., 2001; Krones-Herzig et al., 2005; Yu et al., 2007 Yu et al., , 2009 . With the exception of prostate cancer, in which EGR1 expression has been reported to be increased, most of the examined tumors typically exhibit reduced EGR1 expression; some of these include glioblastoma, lymphoma, breast and lung cancer, and more recently rhabdomyosarcoma (Huang et al., 1997; Virolle et al., 2003; Roeb et al., 2007) . In many of these tumors, the mechanisms underlying EGR1 downregulation are poorly defined. Recently, we reported that the synovial sarcoma-associated SS18-SSX fusion oncoprotein dominantly inhibits EGR1 transcription through polycombmediated chromatin remodeling (Lubieniecka et al., 2008) . It is noteworthy that HDAC inhibitors, a new class of anticancer drugs (Moradei et al., 2008; Stimson et al., 2009) , can reverse this process. In this study, we show that EGR1 reactivation by HDAC inhibitors has a causal function in the induction of synovial sarcoma cell death by these compounds. Furthermore, these analyses have revealed a critical role for EGR1 suppression by the SS18-SSX fusion oncoprotein in the etiology of synovial sarcoma.
EGR1 and synovial sarcoma biology EGR1 expression is reduced or absent in a large number of tumors and cell lines. Reexpression of EGR1 in some of these cells leads to growth arrest, differentiation or cell death, indicating that EGR1 has a fundamental role in the biology of these tumors. Recent studies of the PAX3-FOXO1 fusion oncoprotein in alveolar rhabdomyosarcoma have shown that PAX3-FOXO1 inhibits cell cycle arrest by attenuating the expression of p57kip2 (CDKN1C), an EGR1 target gene (Roeb et al., 2007 (Roeb et al., , 2008 . Interestingly, in this tumor, EGR1 expression is not affected, but the fusion oncoprotein interacts with EGR1 and promotes its degradation; neither of the wild-type constituents of the fusion oncoprotein interact with EGR1. The importance of EGR1 suppression in this tumor was highlighted by the findings that reexpression of EGR1 in a rhabdomyosarcoma-derived cell line enhanced exit from the cell cycle and subsequent cell differentiation. In synovial sarcoma, a similar picture is beginning to emerge with respect to the importance of EGR1 in the biology of this tumor type. The analysis of HDAC inhibitor action in synovial sarcoma has provided unparalleled insights into the underlying tumorgenic mechanisms of the SS18-SSX fusion oncoprotein. In particular, reactivation of EGR1 with HDAC inhibitors or subsequent studies involving specific heterologous expression of EGR1 or its downstream target PTEN significantly increased cell death. Together, these findings indicate that the SS18-SSX fusion oncoprotein through repression of EGR1 enables synovial sarcoma cells to escape normal apoptotic cues. Thus, the fusion oncoproteins in these disparate sarcomas converge on a common target, EGR1, to subvert normal cell differentiation and cell death pathways.
EGR1-PTEN pathway and regulation of apoptosis in synovial sarcoma
Although the activation of PTEN greatly contributes to the apoptotic response of cancer cells to HDAC inhibitor treatment, the exact mechanism underlying this process has not been defined. Because PTEN expression can be directly regulated by the EGR1 transcription factor (Virolle et al., 2001) , we speculated that activation of EGR1 by HDAC inhibitors might elevate the expression of PTEN and in turn stimulate apoptosis. In this study, we show that HDAC inhibitors effectively upregulate the expression of PTEN in wildtype, but not in EGR1-knockdown, synovial sarcoma cells. It is of note that after addition of HDAC inhibitors, the EGR1 protein time dependently binds to a functional cis-acting element in the PTEN promoter, which tightly correlates with an increase in EGR1 and PTEN in Synovial Sarcoma L Su et al PTEN mRNA and protein levels. As in the case of EGR1, a significant decrease in HDAC inhibitorinduced apoptosis is observed in PTEN-knockdown synovial sarcoma cells. Thus, direct regulation of PTEN by EGR1 at least partly explains the ability of HDAC inhibitors to induce apoptosis. Along with activation of PTEN, we also found that AKT phosphorylation is downregulated by HDAC inhibitor treatment, but is strongly protected by repression of EGR1. Given that the PI3K/AKT survival pathway is biologically active in synovial sarcoma (Bozzi et al., 2008) , this observation further supports the functional significance of PTEN in an EGR1-dependent apoptotic response to HDAC inhibitors. In fact, a similar regulatory mechanism whereby EGR1 directly transactivates PTEN has been discovered under stressors such as radiation and etoposide in other model systems (Virolle et al., 2001; Kim et al., 2006; Yu et al., 2009) . It is tempting to speculate that the connection between EGR1 and PTEN may be a common mechanism underlying the apoptotic response of many human tumors to radiation and chemotherapy. Although we identify an HDAC inhibitor-induced pathway for PTEN induction by EGR1, we cannot rule out the possibility that EGR1 may also suppress tumor growth through one or more PTEN-independent pathways following HDAC inhibitor treatment. Consistent with this, efficient knockdown of PTEN (Figure 5a ) only leads to an B50% reduction in cell death (Figure 6b ), indicating that other pathways in addition to PTEN are likely to contribute to HDAC-induced cell death. Earlier studies have shown that EGR1 functionally activates the p53-mediated cell death pathway both in vitro and in vivo (Nair et al., 1997; Krones-Herzig et al., 2005) . However, under our conditions, the HDAC inhibitor romidepsin does not markedly affect the expression of either p53 or its negative regulator MDM2 in synovial sarcoma cells (data not shown). This could be consistent with the finding that HDAC inhibitor-mediated acetylation of the EGR1 protein reduces its capacity for p53 transactivation (Yu et al., 2004) . Interestingly, we noticed a clear increase in C-terminal modifications of p53 after addition of romidepsin (data not shown). In fact, six lysine residues have been identified at the Cterminus of human p53, all of which can be acetylated by many HDAC inhibitors (Zhao et al., 2006; Roy and Tenniswood, 2007; Condorelli et al., 2008) . Growing evidence suggests that acetylated p53 physically associates with EGR1, which in turn enhances the stability and transcriptional activation capacity of p53 (Liu et al., 2001; Habold et al., 2008) . Future studies will assess whether p53 is involved in HDAC inhibitor-induced EGR1-dependent apoptosis of synovial sarcoma and how p53 regulates downstream target genes in the EGR1 network.
In summary, our present studies show a central role of the transcription factor EGR1 in synovial sarcoma cell survival and HDAC inhibitor-induced apoptotic effects on synovial sarcoma. Given that current doxorubicin/ ifosphamide-based chemotherapy has limited benefit in synovial sarcoma patients (Italiano et al., 2009) , our findings suggest that HDAC inhibitors are worth evaluating as a targeted inhibitor of the oncogenic effects of SS18-SSX through restoration of EGR1 and PTEN expressions.
Materials and methods
Cells and chemicals
Synovial sarcoma cell lines SYO-1 and FUJI (kindly provided by Dr Kazuo Nagashima, Hokkaido University School of Medicine, and Dr Akira Kawai, National Cancer Centre Hospital, Tokyo, Japan) and human embryonic kidney HEK293 cells were cultured in RPMI-1640 and DMEM media (Invitrogen, Grand Island, NY, USA), respectively. Stable HEK293 cell lines expressing Myc-tagged His, SS18 or SS18-SSX2 were grown in DMEM with 400 mg/ml Zeocin (Invitrogen). All media were supplemented with 10% fetal bovine serum (Invitrogen), and all cells were maintained at 37 1C, 95% humidity, 5% CO 2 .
HDAC inhibitors romidepsin (FK228, depsipeptide and NSC-630176), MS-275, PXD101 and SAHA were obtained through the Developmental Therapeutic Branch of the National Cancer Institute (Bethesda, MD, USA). Cycloheximide and z-VAD-fmk were purchased from BioVision (Mountain view, CA, USA) and Promega (Madison, WI, USA), respectively.
RT-qPCR analysis Total RNA was isolated and then transcribed to cDNA using the RNeasy Mini kit (Qiagen, Alameda, CA, USA) and the high-capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA). Taqman gene expression assays were carried out using the ABI 7500 Fast Real-Time PCR system with primer/probe sets specific for EGR1, PTEN or 18S ribosomal RNA (rRNA) (Applied Biosystems). All RT-qPCR data were normalized to 18S rRNA.
Western blots
Cells were lysed with the SDS lysis buffer (Millipore, Billerica, MA, USA). Proteins were separated on 10-12% sodium dodecyl sulfate-poly acrylamide gel electrophoresisgels, and transferred to nitrocellulose membranes (Bio-Rad Laboratories, Mississauga, ON, Canada). Blots were incubated with antibodies specific to caspase-3, AKT, p-AKT (Serine 473), EGR1 (Cell Signaling Technology, Danvers, MA, USA), PTEN and actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Signals were visualized using the Odyssey Infrared System (LI-COR Biosciences, Lincoln, NE, USA).
RNAi
The EGR1-specific and control random small interfering RNAs (siRNAs) were purchased from Dharmacon (Lafayette, CO, USA), and the PTEN-specific siRNA from Cell Signaling Technology. At 60% confluence, cells were transfected with the EGR1, PTEN or control random siRNA using Lipofectamine RNAiMAX transfection reagent (Invitrogen) according to the manufacturer's instructions. After culturing for 24 h, cells were treated with HDAC inhibitors, and analyzed by western blotting or RT-qPCR to determine knockdown efficiency.
Plasmids and transfection
The EGR1 and PTEN cDNA (Invitrogen) were inserted into a Gateway pENTR1A vector, followed by recombineering into the internal ribosome entry site-EGFP expression constructs EGR1 and PTEN in Synovial Sarcoma L Su et al by LR site-specific recombination reaction (Invitrogen). Cells were grown on 24-well plates to 60% confluence, and transfected with EGR1, PTEN or empty vector using Fugene 6 transfection reagent (Roche, Laval, QC, Canada) . At 48 h after transfection, EGFP-expressing cells were visualized under epifluorescence, and EGR1 or PTEN proteins were detected by western blotting analysis.
Cell death and apoptosis assay Cells were grown on 96-well plates, and stained with PI at a concentration of 500 ng/ml. After indicated treatments, PIpositive cells were detected and counted over time by a highcontent screening system (KineticScan HCS Reader, Cellomics, Inc.). In other gene knockdown or overexpression assays, cells were cultured with PI on 24-well plates and transfected with the indicated siRNA, or plasmid. PI-positive cells were counted under a fluorescence microscope and then normalized to EGFP-positive cells (at least 500 cells scored for each experiment) to give the percentage of cell death. For apoptosis assays, after treatment, cells were harvested and resuspended in annexin V-FITC-PI dye (Invitrogen). After the addition of annexin V-binding buffer, the samples were run through a FACS scan flow cytometer (Becton Dickinson, Mississauga, ON, Canada). Summit for MoFlo Acquisition and Sort Control Software (Cytomation, Inc.) were used to quantify apoptosis.
ChIP analysis
ChIP assays were performed using the Active Motif ChIP-IT kit as described (Lubieniecka et al., 2008) . EGR1-chromatin complexes were immunoprecipitated using the EGR1 (588) antibody (Santa Cruz Biotechnology). Specific sequences of the human PTEN promoter were amplified by PCR using the following primers: 5 0 -CTCGGTCTTCCGAGGC-3 0 and 5 0 -CC GAGCGCGTATCCTG-3 0 for P1, 5 0 -AAACGAGCCGAGTT ACCG-3 0 and 5 0 -GACTGCATTCGCTCTTTCCT-3 0 for P2, as described elsewhere (7, 31).
Establishment of stable EGR1-knockdown cell lines
The EGR1 and control random small hairpin RNA (shRNA) lentiviral vectors were purchased from Open Biosystems. After transfection of plasmids into the packaging cell line, TLA-HEK293T, the lentiviral supernatant was transduced in the biphasic synovial sarcoma cell line, SYO-1. Cells were maintained in puromycin (2 mg/ml)-containing RPMI-1640 media with 10% fetal bovine serum. Puromycin-resistant colonies were isolated, and after HDAC inhibitor treatment, EGR1 expression was analyzed by western blot.
